Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial

2017 ASCO Annual Meeting
Tweet this page

Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)

Advertisement

Advertisement



Advertisement